Biomedical Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44-7360-538437

Case Report - Biomedical Research (2018) Volume 29, Issue 12

Anaphylaxis due to food-related anaphylaxis treated with omalizumab

Anaphylaxis is a systemic allergic reaction that is acute and could be life-threatening. Once diagnosed, avoidance of allergen and carrying an epinephrine auto-injector are recommended. Most anaphylactic reactions are immunoglobulin E (IgE)-mediated and the major triggers include food, medication, insect stings, exercise and vaccines. Here, we present a case of a 38-year-old male, a surgeon, diagnosed as food-related anaphylaxis with a convincing clinical history and the positive serum-specific IgE level to Dermatophagoides pteronyssinus and Dermatophagoides farina allergens. This patient was treated with omalizumab administered subcutaneously. Routine lymphocyte subsets and CD23+ B cells of this patient were evaluated monthly for the consecutive ten months and one year after the last treatment. Our data showed that there was a correlation between the level of CD23+ B cells and the efficacy of omalizumab treatment. The patient had higher percentage of CD23+ B cells and CD23 expression level (86.5 % and MFI 371.9, respectively) during the onset of anaphylaxis. With the omalizumab treatment, both CD23+ B cells and CD23 expression level decreased gradually. The basal levels of CD23+ B cells and CD23 expression dropped to 25.1% and 72.6 MFI, respectively when the patient became recovered one year after the last treatment. Our findings highlight the potential of CD23+ B cells to be the useful parameter to predict the treatment effect of omalizumab in food-related anaphylaxis.

Author(s): Hui Chien Lai, Kuan-Hua Chu, Su-Boon Yong

Abstract Full Text PDF

Get the App